MRD poster presented at international AML conference

2023 Munich AML conference poster_Rarity_cut

CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the AML Conference in Munich, Germany 2023, to engage and discuss the main topics of this year such as novel target therapies and markers for Diagnosis and Prognosis. Linus Bosaeus and Lei Chen are there Monday til Wednesday and present poster #79, demonstrating positive […]

Open position at Rarity Bioscience

team Rarity Bioscience

We are aiming at radically improving cancer diagnostic and are expanding our Research and Development team, we need you as our Scientist! What we offer We are a young and fast-growing company with an agile cross functional work environment. We promise you dedicated and performance oriented colleagues, a lot of responsibility and the possibility to […]

New assay available in our product portfolio


Using the superRCA technology, you can essentially detect any known sequence of interest using target specific ligation templates and padlock probes. The assay work on purified DNA coming from various types of samples, including cfDNA from liquid biopsies. Targets may be hotspot mutations, private driver mutations, or simply any sequence of interest. We now have […]

Collaboration project for better health is progressing strongly


Last spring, Rarity was awarded a grant from Swelife and Medtech4Health. The idea is to study superRCA for precision diagnostics and relapse detection for Acute Myeloid Leukemia and Myelodysplastic syndrome – ultimately improving treatment outcome, reducing patient burden and cost. Part of the project aims to benchmark superRCA against ddPCR and investigate to what extent […]

Novalis Biotech invests in Rarity Bioscience’s
ultra sensitive genomics technology

Wim Van Criekinge, Co-Founder and Managing Director at Novalis_Linus Bosaeus, CEO at Rarity Bioscience

To further accelerate growth, Rarity Bioscience announces today a new strategicinvestment from Belgium based Novalis Biotech. The investment is facilitated as anoversubscription of the recent round closed in November 2022. Apart from previousowner, that round also included Wallenberg Investments through Navigare Venture,now bringing the total investment round to €3M. Novalis Biotech (Ghent, Belgium) is an […]

Rarity Bioscience raises €2,5M in seed funding to improve cancer care

Linus Bosaeus, CEO Rarity Bioscience

With the aim to improve cancer diagnostics, Rarity Bioscience has raised €2,5 million to expand operations and product development within precision diagnostics and liquid biopsy. The seed round was led by founders and joined by new investor, Navigare Ventures, owned by Wallenberg Investments AB. This investment round has come after a successful first year establishing […]

Free analysis for cancer researchers

Movember cancer

During November, Rarity Bioscience offer free analysis of liquid biopsy samples for cancer research. Movember is a month-long event to raise awareness of men’s health issues, and we want to do our part. Movember aims to increase early cancer detection, diagnosis, effective treatments and ultimately reduce the number of preventable deaths. At Rarity Bioscience, our vision […]

Podcast: Towards better health with Rarity

Speed of life podcast- Abe_Linus

Speed of Life is a podcast series focusing on innovations accelerating towards better health, by STUNS Life Science. It’s sponsored through a project funded by European Regional Development Fund (ERDF), Region Uppsala and STUNS Life Science. Rarity Bioscience, was invited to share our story. Our CTO and founder Lei Chen and Linus Bosaeus, CEO, were […]

One year: Research, innovation and improved patient outcome

Rarity Bioscience - året som gått

Rarity Bioscience was founded in July 2021 based on an innovation by Dr. Lei Chen and Professor Ulf Landegren. Linus Bosaeus was appointed as the CEO and shortly after, the seed round was raised. Since the start, the operational team has grown from two to eight employees and is still growing. Rarity celebrates one year […]

Best Poster Award 2022 at European Society for Medical Oncology

CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the European Society for Medical Oncology Congress 2022, to learn more about the latest advancements in Liquid Biopsy and Minimal Residual Disease and make new contacts in the field. Dr. Lei Chen presented poster #629P; Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection […]